Chemomab Therapeutics (CMMB) Enterprise Value (2017 - 2025)
Chemomab Therapeutics posted quarterly Enterprise Value of -$10.4 million for Q4 2025, down 68.64% year-on-year from -$33.0 million in Q4 2024, and down 45.53% on a QoQ basis from -$7.1 million in Q3 2025.
Chemomab Therapeutics (CMMB) has 9 years of Enterprise Value data on file, last reported at -$10.4 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 68.64% year-over-year to -$10.4 million; the trailing twelve-month figure through Dec 2025 stood at -$10.4 million (down 68.64% YoY), and the FY2025 full-year result was -$10.4 million, down 68.64% from the prior year.
- Enterprise Value for Q4 2025 stood at -$10.4 million, down from -$7.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$4.7 million in Q1 2024 and bottomed at -$66.9 million in Q2 2021.
- The 5-year median for Enterprise Value is -$10.4 million (2023), against an average of -$24.5 million.
- The widest annual swing landed in 2021, when Enterprise Value slumped 849.59%; it then soared 85.51% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$15.2 million in 2021, then increased by 10.47% to -$13.6 million in 2022, then surged by 31.1% to -$9.4 million in 2023, then surged by 34.38% to -$6.1 million in 2024, then plunged by 68.64% to -$10.4 million in 2025.
- The last three Enterprise Value figures came in at -$10.4 million (Q4 2025), -$7.1 million (Q3 2025), and -$5.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | -10.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.37 Mn |
| Sep 30, 2025 | -7.12 Mn |
| Jun 30, 2025 | -5.74 Mn |
| Mar 31, 2025 | -8.48 Mn |
| Dec 31, 2024 | -6.15 Mn |
| Sep 30, 2024 | -6.68 Mn |
| Jun 30, 2024 | -5.18 Mn |
| Mar 31, 2024 | -4.74 Mn |
| Dec 31, 2023 | -9.37 Mn |
| Sep 30, 2023 | -9.23 Mn |
| Jun 30, 2023 | -10.46 Mn |
| Mar 31, 2023 | -32.71 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | -46.54 Mn |
| Jun 30, 2022 | -51.72 Mn |
| Mar 31, 2022 | -57.41 Mn |
| Dec 31, 2021 | -15.19 Mn |
| Sep 30, 2021 | -64.27 Mn |
| Jun 30, 2021 | -66.92 Mn |
| Mar 31, 2021 | -58.20 Mn |
| Dec 31, 2020 | -11.70 Mn |
| Sep 30, 2020 | -6.77 Mn |
| Jun 30, 2020 | -8.82 Mn |
| Mar 31, 2020 | -14.14 Mn |
| Dec 31, 2019 | -17.58 Mn |
| Sep 30, 2019 | -32.41 Mn |
| Jun 30, 2019 | -28.88 Mn |
| Mar 31, 2019 | -32.13 Mn |
| Dec 31, 2018 | -14.49 Mn |
| Sep 30, 2018 | -1.45 Mn |
| Jun 30, 2018 | -1.45 Mn |
| Dec 31, 2017 | -1.45 Mn |